By Andrei Skvarsky.
Private equity investment firms Permira and Ampersand, based in London and Boston respectively, and the Abu Dhabi Investment Authority (ADIA) have jointly acquired and merged two global pharmaceutical companies making remedies from human blood plasma.
The merger of Kedrion Biophama, which is headquartered in Tuscany, Italy, and Bio Products Laboratory (BPL), which is based in Hertfordshire, England, “creates a global player for medicinal products derived from human blood plasma, which treat patients with rare and life-threatening conditions”, Permira and Ampersand said in a joint statement.
Sorry, comments are closed for this post.